(PubMed) Boehnke C, Reuter U, Flach U, Schuh-Hofer S, Einhaupl KM, Arnold G
otherwise 100,- Zone 1 (EU) including Switzerland and United Kingdom (GB): Belgium, Bulgaria, Denmark (except Faroe Islands, Greenland), Estonia, Finland (except land Islands), France (except overseas territories and departments), Greece (except Mount Athos), United Kingdom (GB, except Channel Islands), Ireland, Italy (except Livigno and Campione d'Italia), Croatia, Latvia, Lithuania, Luxembourg, Malta, Monaco, Netherlands (except non-European territories), Austria, Poland, Portugal, Romania, Sweden, Slovakia, Slovenia, Spain (except Canary Islands, Ceuta + Melilla), Czech Republic, Hungary, Cyprus/Republic (except northern part), including Switzerland Zone 2 (Europe excluding the EU): land Islands (Finland), Andorra, Albania, Armenia, Azerbaijan, Mount Athos (GR), Bosnia and Herzegovina, Campione d'Italia (IT), Ceuta (E), Faroe Islands (DK), Georgia, Gibraltar (GB), Greenland (DK), Guernsey (GB), Iceland, Jersey (GB), Canary Islands (E), Kazakhstan , Kosovo (Serbian province), Liechtenstein, Livigno (IT), Macedonia, Melilla (E), Moldova (Republic), Montenegro (Republic), Norway, Russian Federation, San Marino, Serbia (Republic), Turkey, Ukraine, Vatican City, Belarus, Cyprus/Republic (northern part) Zone 3 (World): Egypt, Algeria, Bahrain, Iran, Iraq, Israel, Yemen, Jordan, Canada, Qatar, Kuwait, Lebanon, Libya, Morocco, Oman, Saudi Arabia, Syria Tunisia, USA, United Arab Emirates Zone 4 (Rest of the world): All countries and territories not assigned to Zones 1, 2 or 3
Copying or distribution is strictly prohibited
According to epidemiological analysis, acne currently affects up to 20.5% of the global population, with its incidence rates continuing to increase rapidly [4, 5]
